A kidney-specific genome-scale metabolic network model for analyzing focal segmental glomerulosclerosis

Mammalian Genome

Volumn 27, Issue 3-4, 2016, Pages 158-167

  Sohrabi Jahromi, Salma ^a   Marashi, Sayed Amir ^a   Kalantari, Shiva ^b  

^a UNIVERSITY OF TEHRAN   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA N ACETYLGALACTOSAMINIDASE; AMINO ACID; BIOLOGICAL MARKER; CHONDROITIN SULFATE; CYTOCHROME P450; ENZYME INHIBITOR; KERATAN SULFATE; PROTEOME; PYRIDOXINE; SIASTATIN B; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ADULT; ALGORITHM; ARTICLE; BIOSYNTHESIS; CELL METABOLISM; CHILD; DRUG TARGETING; END STAGE RENAL DISEASE; ENZYME INHIBITION; FLUX VARIABILITY ANALYSIS; FOCAL GLOMERULOSCLEROSIS; GENE EXPRESSION; GENETIC DISORDER; GENOME; HUMAN; MATHEMATICAL ANALYSIS; MODEL; TISSUE SPECIFICITY; BIOLOGICAL MODEL; DRUG DEVELOPMENT; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMAN GENOME; METABOLISM; PROCEDURES;

ALGORITHMS; BIOMARKERS; DRUG DISCOVERY; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MODELS, BIOLOGICAL;

EID: 84959342877     PISSN: 09388990     EISSN: 14321777     Source Type: Journal    
DOI: 10.1007/s00335-016-9622-2     Document Type: Article

References (54)

1. Abeling N et al (2000) Pathobiochemical implications of hyperdopaminuria in patients with aromatic l-amino acid decarboxylase deficiency. J Inherit Metab Dis 23(4):325–328
2. Bailey CG et al (2011) Loss-of-function mutations in the glutamate transporter SLC1A1 cause human dicarboxylic aminoaciduria. J Clin Investig 121(1):446–453
3. Bennett MR et al (2007) Laser capture microdissection-microarray analysis of focal segmental glomerulosclerosis glomeruli. Nephron Exp Nephrol 107(1):e30–e40
4. Blériot Y et al (2014) Synthesis of 1,2-cis-homoiminosugars derived from GlcNAc and GalNAc exploiting a β-amino alcohol skeletal rearrangement. Org Lett 16(21):5512–5515
5. Çakır T, Khatibipour MJ (2014) Metabolic network discovery by top-down and bottom-up approaches and paths for reconciliation. Front Bioeng Biotechnol 2:62
6. Chang RL et al (2010) Drug off-target effects predicted using structural analysis in the context of a metabolic network model. PLoS Comput Biol 6(9):e1000938
7. D’Agati VD, Kaskel FJ, Falk RJ (2011) Focal segmental glomerulosclerosis. N Engl J Med 365(25):2398–2411
8. Duarte NC et al (2007) Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc Natl Acad Sci USA 104(6):1777–1782
9. Fornoni A, Merscher S, Kopp JB (2014) Lipid biology of the podocyte: new perspectives offer new opportunities. Nat Rev Nephrol 10(7):379–388
10. Funderburgh J, Caterson B, Conrad G (1987) Distribution of proteoglycans antigenically related to corneal keratan sulfate proteoglycan. J Biol Chem 262(24):11634–11640
11. Hadi M, Marashi S-A (2014) Reconstruction of a generic metabolic network model of cancer cells. Mol BioSyst 10(11):3014–3021
12. Hao C-M, Breyer MD (2008) Physiological regulation of prostaglandins in the kidney. Annu Rev Physiol 70:357–377
13. Hao X et al (2013) Distinct metabolic profile of primary focal segmental glomerulosclerosis revealed by NMR-based metabolomics. PLoS One 8(11):e78531
14. Hodgin JB et al (2010) A molecular profile of focal segmental glomerulosclerosis from formalin-fixed, paraffin-embedded tissue. Am J Pathol 177(4):1674–1686
15. Ichida K et al (2012) Mutations associated with functional disorder of xanthine oxidoreductase and hereditary xanthinuria in humans. Int J Mol Sci 13(11):15475–15495
16. Jerby L, Ruppin E (2012) Predicting drug targets and biomarkers of cancer via genome-scale metabolic modeling. Clin Cancer Res 18(20):5572–5584
17. Jones G, Prosser DE, Kaufmann M (2014) Cytochrome P450-mediated metabolism of vitamin D. J Lipid Res 55(1):13–31
18. Kanwar YS, Linker A, Farquhar MG (1980) Increased permeability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparan sulfate) by enzyme digestion. J Cell Biol 86(2):688–693
19. Kim HU, Sohn SB, Lee SY (2012a) Metabolic network modeling and simulation for drug targeting and discovery. Biotechnol J 7(3):330–342
20. Kim TY et al (2012b) Recent advances in reconstruction and applications of genome-scale metabolic models. Curr Opin Biotechnol 23(4):617–623
21. Kitiyakara C, Kopp JB, Eggers P (2003) Trends in the epidemiology of focal segmental glomerulosclerosis. Semin Nephrol 23(2):172–182
22. Klein T, Klaus G, Kömhoff M (2015) Prostacyclin synthase: upregulation during renal development and in glomerular disease as well as its constitutive expression in cultured human mesangial cells. Mediat Inflamm 2015:654151
23. Kopple JD et al (1981) Daily requirement for pyridoxine supplements in chronic renal failure. Kidney Int 19(5):694–704
24. Lenz O, Elliot SJ, Stetler-Stevenson WG (2000) Matrix metalloproteinases in renal development and disease. J Am Soc Nephrol 11(3):574–581
25. Lewis NE et al (2010) Large-scale in silico modeling of metabolic interactions between cell types in the human brain. Nat Biotechnol 28(12):1279–1285
26. Mardinoglu A, Gatto F, Nielsen J (2013) Genome-scale modeling of human metabolism–a systems biology approach. Biotechnol J 8(9):985–996
27. Mardinoglu A et al (2014) Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease. Nat Commun 5:3083
28. McCormick DB, Chen H (1999) Update on interconversions of vitamin B-6 with its coenzyme. J Nutr 129(2):325–327
29. McKusick VA (2007) Mendelian Inheritance in Man and its online version, OMIM. Am J Hum Genet 80(4):588–604
30. Merrill AH Jr, Henderson JM (1987) Diseases associated with defects in vitamin B6 metabolism or utilization. Annu Rev Nutr 7(1):137–156
31. Milne CB et al (2009) Accomplishments in genome-scale in silico modeling for industrial and medical biotechnology. Biotechnol J 4(12):1653–1670
32. Morham SG et al (1995) Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83(3):473–482
33. Nafar M et al (2014) The novel diagnostic biomarkers for focal segmental glomerulosclerosis. Int J Nephrol 2014:574261
34. Nishimura Y et al (1996) Synthesis and activity of 1-N-iminosugar inhibitors, siastatin B analogues for α-N-acetylgalactosaminidase and β-N-acetylglucosaminidase. Bioorg Med Chem 4(1):91–96
35. Okamoto N et al (2007) Associations between renal sodium-citrate cotransporter (hNaDC-1) gene polymorphism and urinary citrate excretion in recurrent renal calcium stone formers and normal controls. Int J Urol 14(4):344–349
36. Orth JD, Thiele I, Palsson BØ (2010) What is flux balance analysis? Nat Biotechnol 28(3):245–248
37. Rood IM, Deegens JK, Wetzels JF (2012) Genetic causes of focal segmental glomerulosclerosis: implications for clinical practice. Nephrol Dial Transpl 27(3):882–890
38. Ryu JY, Kim HU, Lee SY (2015) Reconstruction of genome-scale human metabolic models using omics data. Integr Biol 7(8):859–868
39. Schellenberger J, Palsson BØ (2009) Use of randomized sampling for analysis of metabolic networks. J Biol Chem 284(9):5457–5461
40. Schellenberger J et al (2011) Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2. 0. Nat Protoc 6(9):1290–1307
41. Schiavon R et al (1994) Plasma glutathione peroxidase activity as an index of renal function. Clin Chem Lab Med 32(10):759–766
42. Shlomi T (2009) Metabolic network-based interpretation of gene expression data elucidates human cellular metabolism. Biotechnol Genet Eng Rev 26(1):281–296
43. Shlomi T et al (2008) Network-based prediction of human tissue-specific metabolism. Nat Biotechnol 26(9):1003–1010
44. Sindic A et al (2007) Renal physiology of SLC26 anion exchangers. Curr Opin Nephrol Hypertens 16(5):484–490
45. Sugahara K et al (2003) Recent advances in the structural biology of chondroitin sulfate and dermatan sulfate. Curr Opin Struct Biol 13(5):612–620
46. Swan SK et al (2000) Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: a randomized, controlled trial. Ann Intern Med 133(1):1–9
47. Tojo A (2013) The role of the kidney in protein metabolism: the capacity of tubular lysosomal proteolysis in nephrotic syndrome. Kidney Int 84(5):861–863
48. Treberg JR et al (2010) Systemic activation of glutamate dehydrogenase increases renal ammoniagenesis: implications for the hyperinsulinism/hyperammonemia syndrome. Am J Physiol Endocrinol Metab 298(6):E1219–E1225
49. Vinai M, Waber P, Seikaly MG (2010) Recurrence of focal segmental glomerulosclerosis in renal allograft: an in-depth review. Pediatr Transpl 14(3):314–325
50. Vo TD, Lee WP, Palsson BO (2007) Systems analysis of energy metabolism elucidates the affected respiratory chain complex in Leigh’s syndrome. Mol Genet Metab 91(1):15–22
51. Woroniecka KI et al (2011) Transcriptome analysis of human diabetic kidney disease. Diabetes 60(9):2354–2369
52. Yizhak K et al (2013) Model-based identification of drug targets that revert disrupted metabolism and its application to ageing. Nat Commun 4:2632
53. Zachara BA et al (2006) Red blood cell and plasma glutathione peroxidase activities and selenium concentration in patients with chronic kidney disease: a review. Acta Biochim Pol 53(4):663–677
54. Zhang A-D, Dai S-X, Huang J-F (2013) Reconstruction and analysis of human kidney-specific metabolic network based on omics data. BioMed Res Int 2013:187509